Proteros biostructures GmbH today announced that they have entered into a drug discovery research collaboration with Bayer Pharma AG (Bayer). The objective of the collaboration is to identify novel compounds for the treatment of cardiovascular diseases. Discovery efforts on an undisclosed regulatory membrane protein will be driven by Proteros over a 2 year period to meet predefined milestones, while Bayer would be responsible for further preclinical candidate optimization and clinical development. Proteros will receive R&D funding, downstream milestones, and royalties on sales of potential resulting commercial products.
The program is based on Proteros’ structure-guided lead discovery platform which combines structure analysis, medicinal chemistry and other discovery technologies to drive potency, selectivity, and safety of novel lead compounds.
Dr. Peter Reinemer, COO of Proteros, commented: “Regulatory membrane proteins are among the most challenging class of targets for structure guided drug discovery approaches. We are very pleased to partner with Bayer in this important initiative for potential new drug candidates for cardiovascular diseases”.